SG63625A1 - Peptides - Google Patents

Peptides

Info

Publication number
SG63625A1
SG63625A1 SG1996008052A SG1996008052A SG63625A1 SG 63625 A1 SG63625 A1 SG 63625A1 SG 1996008052 A SG1996008052 A SG 1996008052A SG 1996008052 A SG1996008052 A SG 1996008052A SG 63625 A1 SG63625 A1 SG 63625A1
Authority
SG
Singapore
Prior art keywords
peptides
Prior art date
Application number
SG1996008052A
Other languages
English (en)
Inventor
Francois Cardinzux
Frank Gombert
Helmut Schneider
Hermann Gram
Ian Lewis
Paul Ramage
Rainer Albert
Roin Brickenbridge
Rudolf Waelchli
Wilfred Bauer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929215009A external-priority patent/GB9215009D0/en
Priority claimed from GB929226415A external-priority patent/GB9226415D0/en
Priority claimed from GB929226859A external-priority patent/GB9226859D0/en
Priority claimed from GB929226861A external-priority patent/GB9226861D0/en
Priority claimed from GB939301692A external-priority patent/GB9301692D0/en
Priority claimed from GB939301691A external-priority patent/GB9301691D0/en
Priority claimed from GB939307673A external-priority patent/GB9307673D0/en
Priority claimed from GB939308033A external-priority patent/GB9308033D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG63625A1 publication Critical patent/SG63625A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG1996008052A 1992-07-15 1993-07-12 Peptides SG63625A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB929215009A GB9215009D0 (en) 1992-07-15 1992-07-15 Organic compounds
GB929226415A GB9226415D0 (en) 1992-12-18 1992-12-18 Organic compounds
GB929226859A GB9226859D0 (en) 1992-12-23 1992-12-23 Organic compounds
GB929226861A GB9226861D0 (en) 1992-12-23 1992-12-23 Organic compounds
GB939301692A GB9301692D0 (en) 1993-01-28 1993-01-28 Organic compounds
GB939301691A GB9301691D0 (en) 1993-01-28 1993-01-28 Organic compounds
GB939307673A GB9307673D0 (en) 1993-04-14 1993-04-14 Organic compounds
GB939308033A GB9308033D0 (en) 1993-04-19 1993-04-19 Organic compounds

Publications (1)

Publication Number Publication Date
SG63625A1 true SG63625A1 (en) 1999-03-30

Family

ID=27571302

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996008052A SG63625A1 (en) 1992-07-15 1993-07-12 Peptides

Country Status (25)

Country Link
US (2) US20050009147A1 (fr)
EP (1) EP0672057B1 (fr)
JP (1) JP3164463B2 (fr)
KR (1) KR100321651B1 (fr)
CN (1) CN1051769C (fr)
AT (1) AT408100B (fr)
AU (1) AU672790B2 (fr)
CA (1) CA2100423C (fr)
CH (1) CH688195A5 (fr)
CZ (1) CZ286889B6 (fr)
DE (2) DE4393381T1 (fr)
DK (1) DK0672057T3 (fr)
ES (1) ES2150948T3 (fr)
FI (1) FI113872B (fr)
GB (1) GB2269176B (fr)
GR (1) GR3035089T3 (fr)
HK (1) HK1004896A1 (fr)
HU (2) HUT70459A (fr)
IL (1) IL106326A (fr)
NO (1) NO319448B1 (fr)
NZ (1) NZ248137A (fr)
PT (1) PT672057E (fr)
SG (1) SG63625A1 (fr)
SK (1) SK283485B6 (fr)
WO (1) WO1994002510A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
TW273513B (fr) * 1993-10-27 1996-04-01 Chugai Pharmaceutical Co Ltd
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CA2126299C (fr) * 1994-06-20 2000-12-12 Gordon E. Willick Analogues de l'hormone parathyroidienne utilises pour le traitement de l'osteoporose
CO4410206A1 (es) * 1994-07-28 1997-01-09 Sandoz Ag DERIVADOS DE PTH o PTHrP, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
CA2178894A1 (fr) * 1995-06-15 1996-12-16 Tsunehiko Fukuda Derives de la parathormone et leur utilisation
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
EE9900039A (et) * 1996-08-02 1999-08-16 National Research Council Of Canada Paratüreoidhormooni analoogid osteoporoosi raviks
EP1352912A1 (fr) * 1996-08-02 2003-10-15 National Research Council Of Canada Analogues de l'hormone parathyroidienne pour le traitement de l'osteoporose
IL132901A0 (en) 1997-05-14 2001-03-19 Aventis Pharm Prod Inc Peptide parathyroid hormone analogs
WO1999004808A1 (fr) * 1997-07-22 1999-02-04 Chugai Seiyaku Kabushiki Kaisha Medicaments dentaires contenant de la pth
EP1005359B1 (fr) * 1997-09-09 2005-06-15 F. Hoffmann-La Roche Ag GUERISON DE FRACTURES AU MOYEN D'ANALOGUES DE PTHrP
ATE392431T1 (de) 1998-05-05 2008-05-15 Sod Conseils Rech Applic Pth2 rezeptor selektive verbindungen
WO2000023594A1 (fr) 1998-10-22 2000-04-27 The General Hospital Corporation PEPTIDES ET DERIVES PEPTIDIQUES BIOACTIFS DE L'HORMONE PARATHYROIDE (PTH) ET DE LA PROTEINE LIEE A L'HORMONE PARATHYROIDE (PTHrP)
DE69942035D1 (de) 1998-11-25 2010-04-01 Gen Hospital Corp Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
AU2023499A (en) 1998-12-31 2000-07-24 General Hospital Corporation, The Pth receptor and screening assay utilizing the same
US7057012B1 (en) 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
JP2002533115A (ja) * 1998-12-31 2002-10-08 ザ ジェネラル ホスピタル コーポレーション Ｐｔｈ機能的ドメイン結合体ペプチド、それらの誘導体、および新規係留リガンド−レセプター分子
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
AU7734800A (en) 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
US7015195B2 (en) 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
CA2496618A1 (fr) 2002-05-23 2003-12-04 Michael Holick Utilisation d'analogues peptidiques d'hormone parathyroide pour le traitement de l'atrophie vaginale
AU2002951372A0 (en) * 2002-09-13 2002-09-26 St Vincent's Institute Of Medical Research Parathyroid hormone-like polypeptides
US7795220B2 (en) 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
EP1653985A4 (fr) 2003-07-17 2009-08-05 Gen Hospital Corp Analogues d'hormone parathyroide (pth) a conformation contrainte
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
JP5007427B2 (ja) 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
WO2007028633A2 (fr) * 2005-09-08 2007-03-15 Uutech Limited Traitement de l'obesite associee aux diabetes
EP1937716A2 (fr) * 2005-09-08 2008-07-02 Uutech Limited Analogues de polypeptide inhibiteur gastrique comme traitement de la fonction reduite des cellules beta pancreatiques du fait du vieillissement
CA2628945A1 (fr) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Parathormone de l'ours noir et procedes d'utilisation de la parathormone de l'ours noir
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
JP5200027B2 (ja) 2006-10-13 2013-05-15 イーライ リリー アンド カンパニー Ｐｔｈ受容体モジュレーターとしてのペグ化ｐｔｈおよびその使用
AU2008282805B2 (en) 2007-08-01 2014-05-01 Chugai Pharmaceutical Co., Ltd. Screening methods using G-protein coupled receptors and related compositions
KR20110071014A (ko) 2008-10-17 2011-06-27 위스콘신 얼럼나이 리서어치 화운데이션 생물학적으로 활성인 알파-베타 펩티드의 제조 방법
WO2010111617A2 (fr) 2009-03-27 2010-09-30 Van Andel Research Institute Peptides de l'hormone parathyroïdienne et peptides de la protéine apparentée à l'hormone parathyroïdienne ainsi que des procédés d'utilisation
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
RU2604809C2 (ru) 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Аналоги паратиреоидного гормона и их применение
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
AU2012223279A1 (en) * 2011-03-01 2013-09-26 Sloan-Kettering Institute For Cancer Research Parathyroid hormone analogs, compositions and uses thereof
WO2015157508A1 (fr) * 2014-04-09 2015-10-15 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques à activité pth
WO2020132269A1 (fr) 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Pyrazolopyrimidines substituées et purines substituées et leur utilisation en tant qu'inhibiteurs de protéase 1 de traitement spécifique de l'ubiquitine
CA3196564A1 (fr) 2020-10-30 2022-05-05 Hanlan Liu Formes de pyrazolopyrimidines substituees a l'etat solide et leurs utilisations
WO2023066881A1 (fr) 2021-10-18 2023-04-27 Astrazeneca Ab Inhibition de map3k15 pour le traitement et la prévention du diabète

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886132A (en) * 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
US4752585A (en) * 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US5420242A (en) * 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
US5001223A (en) * 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
EP0293158A3 (fr) * 1987-05-26 1990-05-09 Merck & Co. Inc. Antagonistes d'hormone parathyroide
DE3725320A1 (de) * 1987-07-30 1989-02-09 Biotechnolog Forschung Gmbh Expressionsvektoren und verfahren unter deren verwendung zur gewinnung von cro/ss-galaktosidase/pth-fusionsproteinen und von pth
US4968669A (en) * 1988-05-09 1990-11-06 Merck & Co., Inc. Parathyroid hormone antagonists
EP0411096A1 (fr) * 1989-02-23 1991-02-06 Gesellschaft für Biotechnologische Forschung mbH (GBF) Sequences d'adn codant pour des variantes de pth, variantes de pth, vecteur d'expression, hote bacterien, utilisation et composition therapeutique
CA2040264A1 (fr) * 1990-04-12 1991-10-13 Tatsuhiko Kanmera Antagonistes de la parathormone
US5093233A (en) * 1990-04-25 1992-03-03 Merck & Co., Inc. Antagonists with position 13 modification
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JPH0532696A (ja) * 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
WO1992011286A1 (fr) * 1990-12-21 1992-07-09 Allelix Biopharmaceuticals Inc. Variantes d'hormone de parathyroide resistantes a l'oxydation
ES2087323T3 (es) * 1991-02-19 1996-07-16 Takeda Chemical Industries Ltd Metodo para producir peptidos exentos de cisteina.
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis

Also Published As

Publication number Publication date
HU9500115D0 (en) 1995-03-28
NO950123D0 (no) 1995-01-12
JP3164463B2 (ja) 2001-05-08
HU211856A9 (en) 1995-12-28
WO1994002510A3 (fr) 1994-05-26
FI950171A0 (fi) 1995-01-13
US20080318838A1 (en) 2008-12-25
FI950171A (fi) 1995-03-13
PT672057E (pt) 2001-02-28
GB2269176A (en) 1994-02-02
WO1994002510A2 (fr) 1994-02-03
NO950123L (no) 1995-03-15
CH688195A5 (de) 1997-06-13
AU4156693A (en) 1994-01-20
SK4395A3 (en) 1995-06-07
GR3035089T3 (en) 2001-03-30
NZ248137A (en) 1995-12-21
CN1099801A (zh) 1995-03-08
CA2100423A1 (fr) 1994-01-16
CA2100423C (fr) 2005-06-14
KR940005670A (ko) 1994-03-22
JPH06184198A (ja) 1994-07-05
KR100321651B1 (ko) 2002-05-13
IL106326A (en) 1997-09-30
AT408100B (de) 2001-08-27
CN1051769C (zh) 2000-04-26
IL106326A0 (en) 1994-04-12
AU672790B2 (en) 1996-10-17
CZ286889B6 (en) 2000-07-12
GB9314384D0 (en) 1993-08-25
CZ8895A3 (en) 1995-10-18
DE4393381B4 (de) 2008-07-17
GB2269176B (en) 1997-01-08
DE4393381T1 (de) 1995-04-27
ES2150948T3 (es) 2000-12-16
DK0672057T3 (da) 2000-12-27
HUT70459A (en) 1995-10-30
EP0672057B1 (fr) 2000-09-20
US20050009147A1 (en) 2005-01-13
NO319448B1 (no) 2005-08-15
SK283485B6 (sk) 2003-08-05
FI113872B (fi) 2004-06-30
EP0672057A1 (fr) 1995-09-20
ATA903993A (de) 2001-01-15
HK1004896A1 (en) 1998-12-11

Similar Documents

Publication Publication Date Title
GB2269176B (en) Peptides
ZA928511B (en) Peptides
IL108169A0 (en) New peptides
GB9226065D0 (en) Peptides
IL108353A0 (en) Novel peptides
ZA915978B (en) Peptides
HU9301768D0 (en) Linear peptides
ZA931299B (en) Novel peptides
ZA933867B (en) Peptide compounds
GB9211668D0 (en) Peptide compounds
ZA935126B (en) Peptides
GB9210074D0 (en) Peptides
GB9226074D0 (en) Peptide
GB9409335D0 (en) Peptides
ZA94211B (en) Peptides
GB9324818D0 (en) Peptide
ZA933868B (en) Peptide compounds
GB9211676D0 (en) Peptide compounds
GB9211675D0 (en) Peptide compounds
GB9102655D0 (en) New peptides
GB9102818D0 (en) New peptides
ZA94319B (en) Novel peptides
GB9226346D0 (en) Proteins
GB9224588D0 (en) Proteins
GB9227189D0 (en) Proteins